Saturday 17 October 2026
Export ARWR’s income statement to Excel — free account
Arrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024. In the quarter to June 2026, revenue grew 171.0%, EPS fell 7.94%, free cash flow fell 15.4% and total debt rose 259.5%, each against the same quarter a year earlier.
55.90
2.60
−4.44%
Follow ARWR
| Sep '16 | Sep '17 | Sep '18 | Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 4 | 3 | 6 | 1 | 4 | 3 | 2 | 3 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 40.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
2.27 | 2.16 | 51.86 | 14.96 | 41.73 | 11.53 | 5.94 | 1.64 | (1.64) | 2.98 |
P/S ratio |
2,831.07 | 10.47 | 99.53 | 15.67 | 49.29 | 46.84 | 14.33 | 11.64 | 12.77 | 5.56 |
Altman Z″-Score (non-manufacturers) |
(8.09) | (9.18) | (7.59) | 2.84 | 7.18 | (0.75) | (1.47) | (2.87) | (4.57) | 0.82 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 16.42 | 0.00 | 43.84 | 0.00 | 0.00 | 0.00 | 29.41 |
P/Operating CF |
(44.07) | (35.73) | (599.44) | 191.52 | (385.18) | (269.54) | (50.69) | (108.08) | (16.91) | 225.14 |
Beneish M-Score |
— | 172.45 | 4.36 | 3.64 | (1.40) | 1.91 | (3.10) | — | — | — |
P/B ratio |
4.72 | 4.07 | 16.87 | 10.84 | 9.39 | 15.84 | 8.33 | 9.76 | 12.14 | 9.16 |
Price to Tangible BV |
6.16 | 5.44 | 21.01 | 11.65 | 9.72 | 16.39 | 8.57 | 10.12 | 12.71 | 9.29 |
EV/Sales |
2,308.47 | 8.46 | 94.92 | 14.15 | 45.94 | 44.36 | 13.11 | 11.56 | 11.24 | 4.76 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 35.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.90 |
EV/Operating CF |
(5.68) | (11.09) | (32.45) | 13.80 | (42.20) | 35.81 | (23.43) | (18.08) | (4.41) | 21.99 |
EV/FCF |
(5.36) | (8.34) | (31.50) | 14.83 | (37.52) | 41.52 | (16.88) | (8.41) | (3.38) | 25.17 |
Quick Ratio |
3.33 | 3.51 | 6.22 | 2.67 | 7.78 | 2.58 | 2.72 | 3.83 | 6.60 | 4.74 |
Current Ratio |
3.53 | 3.63 | 6.37 | 2.73 | 7.92 | 2.62 | 2.92 | 3.95 | 6.74 | 4.86 |
Net Debt/EBITDA |
1.06 | 1.95 | 1.46 | (3.88) | 3.40 | 2.44 | 1.78 | 0.10 | 0.49 | (5.70) |
Debt/Assets |
2.13% | 2.44% | 2.08% | 0.00% | 4.05% | 3.60% | 11.79% | 50.09% | 34.50% | 18.40% |
Debt/Equity |
0.03 | 0.03 | 0.02 | 0.00 | 0.05 | 0.06 | 0.20 | 1.34 | 2.06 | 0.51 |
Asset Turnover |
0.00 | 0.27 | 0.15 | 0.73 | 0.20 | 0.22 | 0.35 | 0.33 | 0.00 | 0.66 |
Operating CF/Net income |
0.79 | 0.70 | 0.87 | 2.55 | 1.13 | (1.22) | 0.77 | 0.75 | 0.77 | (110.09) |
Capex/Depreciation |
(1.11) | (1.70) | (0.28) | (2.18) | (1.85) | (2.76) | (3.96) | (16.87) | (9.22) | (1.25) |
Interest Coverage |
(307.53) | (89.13) | (53.35) | 8.79 | (10.14) | (24.35) | (35.47) | (11.19) | (18.58) | 1.10 |
| (79.87%) | (39.09%) | (61.84%) | 40.07% | (23.96%) | (32.36%) | (42.57%) | (58.19%) | (250.72%) | (0.47%) | |
| (62.76%) | (29.61%) | (50.50%) | 29.46% | (19.39%) | (22.85%) | (25.11%) | (28.17%) | (62.93%) | (0.13%) | |
ROIC |
(412.49%) | (129.96%) | (166.22%) | 0.00% | (34.78%) | (139.91%) | (90.32%) | (47.98%) | 0.00% | 0.00% |
Return on Tangible Assets |
(101.84%) | (53.13%) | (67.78%) | 35.52% | (27.05%) | (49.12%) | (46.73%) | (34.14%) | (61.28%) | (0.14%) |
Average Days of Receivables |
172.93 | 0.79 | 7.40 | 1.43 | 3.51 | 27.07 | 2.12 | 0.00 | 0.00 | 3.00 |
Research and Development Expense of Revenue |
39,240.56% | 162.08% | 328.13% | 48.02% | 146.46% | 149.21% | 122.23% | 146.71% | 14,245.85% | 73.20% |
Selling, General and Administrative Expense of Revenue |
14,905.18% | 55.72% | 118.39% | 15.73% | 59.41% | 58.56% | 51.16% | 38.44% | 2,781.22% | 14.94% |
Intangible Assets out of Total Assets |
0.17 | 0.20 | 0.17 | 0.05 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
7,325.21% | 25.13% | 52.38% | 7.34% | 49.30% | 55.44% | 49.70% | 32.45% | 2,083.02% | 7.64% |
Graham Net Nets |
0.13 | 0.14 | 0.04 | 0.06 | 0.06 | 0.01 | 0.04 | (0.02) | (0.11) | 0.01 |
Graham Number |
0.00 | 0.00 | 0.00 | 6.35 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(18.10%) | (10.34%) | (3.44%) | 2.45% | (1.95%) | (2.18%) | (5.08%) | (7.35%) | (25.92%) | (0.23%) |
Free Cash Flow Yield |
(15.22%) | (9.69%) | (3.03%) | 6.09% | (2.48%) | 2.28% | (5.42%) | (11.80%) | (26.05%) | 3.40% |
Revenue per Share |
0.00 | 0.43 | 0.19 | 1.80 | 0.87 | 1.33 | 2.31 | 2.26 | 0.03 | 6.20 |
Operating CF per Share |
(1.06) | (0.32) | (0.56) | 1.84 | (0.95) | 1.65 | (1.29) | (1.44) | (3.86) | 1.34 |
Capex per Share |
(0.06) | (0.11) | (0.02) | (0.13) | (0.12) | (0.23) | (0.50) | (1.66) | (1.18) | (0.17) |
Free Cash Flow per Share |
(1.12) | (0.43) | (0.58) | 1.72 | (1.07) | 1.42 | (1.79) | (3.10) | (5.05) | 1.17 |
Cash per Share |
1.40 | 0.89 | 0.92 | 2.76 | 3.13 | 3.55 | 3.57 | 3.78 | 5.68 | 6.87 |
Shareholders Equity per Share |
1.56 | 1.09 | 1.14 | 2.60 | 4.58 | 3.94 | 3.97 | 2.69 | 1.60 | 3.76 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.56 | 1.09 | 1.14 | 2.60 | 4.58 | 3.94 | 3.97 | 2.69 | 1.60 | 3.76 |
Free Cash Flow |
(68.29) | (31.86) | (48.64) | 161.03 | (107.75) | 147.75 | (188.91) | (330.63) | (604.32) | 156.89 |
Working Capital |
64.86 | 49.20 | 66.40 | 168.18 | 281.69 | 238.06 | 266.45 | 311.02 | 592.30 | 755.15 |
Capital Expenditures |
(3.86) | (7.92) | (1.42) | (12.00) | (11.95) | (23.57) | (52.78) | (176.74) | (141.47) | (22.67) |
Net Current Asset Value |
57.35 | 44.75 | 62.40 | 159.44 | 261.65 | 83.27 | 131.70 | (61.92) | (253.27) | 68.76 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 39.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40.15 |
Capex to Sales |
24.39 | 0.25 | 0.09 | 0.07 | 0.14 | 0.17 | 0.22 | 0.73 | 39.84 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 43.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.91 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.23 | 0.30 | 0.36 | 0.24 | 0.21 | 0.18 | 0.12 | 0.04 | 0.04 | 0.05 |
Cash ROIC |
(37.29%) | (21.38%) | (27.94%) | 32.03% | (13.50%) | 18.42% | (21.56%) | (30.78%) | (47.76%) | 9.35% |
Accounts Receivable Turnover |
2.11 | 439.88 | 81.69 | 341.42 | 116.75 | 24.91 | 41.70 | 0.00 | 0.00 | 201.47 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
Average Receivables |
0.08 | 0.07 | 0.20 | 0.49 | 0.75 | 5.55 | 5.83 | — | — | 4.12 |
Average Payables |
8.63 | 8.15 | 3.44 | 5.23 | 7.24 | 8.14 | 6.16 | 19.37 | 23.63 | 14.53 |
Average Assets |
130.22 | 116.10 | 107.82 | 230.73 | 436.17 | 616.33 | 701.04 | 728.75 | 952.68 | 1,262.55 |
Average Common Equity |
102.32 | 87.95 | 88.05 | 169.64 | 352.91 | 435.30 | 413.58 | 352.75 | 239.11 | 347.24 |
Columns are period end dates